Streetbeat News

TMBR

Timber Pharmaceuticals Inc

http://www.thompson-designs.com/

Employees

7

Industry

Medicinal and Botanical Manufacturing

timber pharmaceuticals llc, a clinical-stage medical dermatology company, focuses on the development and commercialization of pharmaceuticals for treatment of orphan dermatologic diseases. the company was founded in 2019 and is based in woodcliff lake, new jersey.

Open

0.34

Mkt cap

1.2M

Volume

130K

High

0.35

P/E Ratio

-0.17

52-wk high

3.39

Low

0.32

Div yield

N/A

52-wk low

0.32

Timber Pharmaceuticals announced the start of delisting proceedings from the NYSE American. Its common stock is expected to trade on the OTC market following the delisting.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 10:27 pm

Timber Pharmaceuticals has received court approval for all 'First Day' motions, which will allow the company to support its business operations during its restructuring process. Additionally, Timber Pharmaceuticals has disclosed that it has received communication from NYSE American, which is likely related to its financial condition and restructuring efforts.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 10:26 pm

Timber Pharmaceuticals Inc has filed for voluntary Chapter 11 bankruptcy protection, according to a court filing. The company has reported both assets and liabilities in the range of $1 million to $10 million.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 9:41 pm

Timber Pharmaceuticals announced that its proposal to approve a merger agreement with Leo US and Leo Spiny Merger Sub was not approved by a majority of the outstanding shares entitled to vote, as per an SEC filing. A special meeting was held to vote on this matter.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 6:19 pm

Trading in shares of Timber Pharmaceuticals has been temporarily halted pending the release of material news from the company.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 5:42 pm

Timber Pharmaceuticals has announced that the New York Stock Exchange (NYSE) has accepted its plan to regain listing compliance. This comes after the company was previously at risk of being delisted due to non-compliance with NYSE's listing standards.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 8:08 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has downgraded Timber Pharmaceuticals from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

August 28, 2023 | 10:14 am

US stocks traded mixed with the Nasdaq Composite gaining around 1.5%. Palo Alto Networks (PANW) reported better-than-expected Q4 earnings and issued a strong billings outlook, causing its shares to rise by 15%. Timber Pharmaceuticals (TMBR) shares shot up 99% as it agreed to be acquired by LEO US Holding. Moderna (MRNA) shares were up 10% as preliminary clinical trial data confirmed its updated COVID-19 vaccine showed a significant boost in neutralizing antibodies. Super League Gaming (SLGG), Napco Security Technologies (NSSC), and Nikola Corporation (NKLA) shares fell by 47%, 47%, and 21% respectively.

Portfolio Pulse from Lisa Levin

August 21, 2023 | 6:51 pm

The article lists the stocks that gained and lost the most in Monday's mid-day session. Among the gainers were China SXT Pharmaceuticals, Timber Pharmaceuticals, and MediaCo Holding, while the losers included AgileThought, Napco Security Technologies, and Super League Gaming. The article also mentions that Palo Alto Networks rose after reporting better-than-expected Q4 earnings and a strong billings outlook, and that Moderna rose after announcing that preliminary clinical trial data confirmed its updated COVID-19 vaccine showed a significant boost in neutralizing antibodies against certain variants.

Portfolio Pulse from Lisa Levin

August 21, 2023 | 6:36 pm

Several healthcare stocks experienced significant price movements during Monday's intraday session. Gainers included Timber Pharmaceuticals (TMBR), China SXT Pharmaceuticals (SXTC), Novo Integrated Sciences (NVOS), China Pharma Holding (CPHI), Fortress Biotech (FBIOP), and Orchestra BioMed Hldgs (OBIO). Losers included CNS Pharma (CNSP), Arcutis Biotherapeutics (ARQT), Modular Medical (MODD), Frequency Therapeutics (FREQ), Vivos Therapeutics (VVOS), and Aziyo Biologics (AZYO).

Portfolio Pulse from Benzinga Insights

August 21, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.